ImmunityBio, Inc.
As of Oct 22, 2026, ImmunityBio is in Stage 2, the uptrend phase, now in week 9 (since Aug 26, 2026). It closed at $8.31, 28.1% below its 52-week high and above its 200-day average, which is rising.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is IBRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IBRX among Biotechnology12th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …12 | IBRX | Stage 2 · wk 9 | 98 | −3.7% |
ImmunityBio: quick answers
What stage is ImmunityBio in?
As of Oct 22, 2026, ImmunityBio (IBRX) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 26, 2026 and is in week 9. What the four stages mean
Is ImmunityBio in an uptrend?
Yes. ImmunityBio is in a Stage 2 uptrend. It trades 7.6% above its 200-day average, which is rising.
How far is ImmunityBio from its 52-week high?
ImmunityBio closed at $8.31 on Oct 22, 2026, 28.1% below its 52-week high of $11.55. Its 52-week low is $1.98.
How has ImmunityBio performed over the past year?
As of Oct 22, 2026, ImmunityBio is up 240.6% over the past year and up 311.4% so far in 2026.
Which sector and industry is ImmunityBio in?
ImmunityBio is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.